Israel sees decline in efficacy of Pfizer vaccine 0:44
The overall effectiveness of coronavirus vaccines has yet to decline much for most vaccinated Americans, vaccine advisers at the U.S. Centers for Disease Control and Prevention told Monday, CDC.
CDC's Advisory Committee on Immunization Practices (ACIP) met Monday to discuss the possible eventual need for booster doses of the coronavirus vaccine, although they did not vote.
The White House has said it plans to offer booster doses in late September, although it is up to the US Food and Drug Administration (FDA) and the CDC to decide on that.
So far, in the data going through July, vaccines still appear to provide robust protection, Dr. Sara Oliver of the CDC told ACIP on Monday.
"Since the introduction of the delta variant, the efficacy of the vaccine against infection ranges between 39 and 84%. However, the effectiveness against hospitalization remains high, between 75% and 95%," said Oliver. , citing global data.
Vaccine efficacy is maintained
"Regardless of the vaccine evaluated, all vaccines are still effective in preventing hospitalizations and serious illness. But they may be less effective in preventing recent mild infections and illnesses," Oliver added.
"These reasons for less effectiveness probably include both the decline over time and the delta variant."
A study in the United States showed that the effectiveness of the vaccine against hospitalization in adults 65 and older may have decreased, but only slightly, over time, he said.
Unpublished data from the CDC shows that the vaccine's effectiveness remains very high, 94% or more in adults ages 18 to 74, he said.
"Preliminary efficacy of the vaccine against hospitalization in adults 75 and older ... declined in July, but still remained above 80%," Oliver said.
The vaccine's effectiveness has dropped from 75% at first to just over 50% among residents of long-term care facilities, Oliver said.
These were the first people vaccinated after the vaccines became available in December and January.
"The data we have seen today has shown that covid vaccines continue to maintain high protection against serious illness, hospitalization and death from covid-19. Protection against infections, including mild and asymptomatic infections, appears to be lower in recent months. ", said.
Moderna and Pfizer Vaccines Highly Effective in Preventing Symptomatic Covid-19, Study Finds
FDA Approves Full Use of Pfizer 2:36 Vaccine
Is there a need for a booster shot?
The three companies that make vaccines for the US market, Pfizer / BioNTech, Moderna and Johnson & Johnson, are evaluating the effects of booster doses, he said.
The main questions are whether booster doses are safe and work to improve protection, he said.
"Will booster doses of COVID-19 vaccines reduce the incidence, hospitalization and / or mortality of COVID-19?" She asked.
The ACIP will meet in the coming weeks to discuss vaccine efficacy data in August, Oliver said.
"We will announce meetings as soon as we have dates," said Dr. Amanda Cohn of the CDC at the end of Monday's meeting.
The CDC and FDA approved the use of boosters in certain immunosuppressed people earlier this month.
While the White House has pushed for booster doses to be offered more widely, the CDC and FDA are waiting for more information from the companies.
But White House officials say they are analyzing data from both Israel and the United States, and they want to be sure they are ahead of any changes in the pandemic.
Israel offers COVID-19 booster doses to everyone 12 and older
Do the Israelis want a third dose of Pfizer?
On Monday, Israel began offering a booster dose to everyone over the age of 12 who had been vaccinated at least five months ago.
Researchers in Israel reported Monday that people who opted for a third dose of the vaccine had a much lower risk of becoming infected, even as the more transmissible delta variant spread across the country.
"Conclusions: Along with the safety reports, this study demonstrates the efficacy of a third dose of vaccine in reducing transmission and severe disease and indicates the great potential to reduce the delta variant resurgence through the administration of booster doses." , wrote Yair Goldberg of the Israel Institute of Technology and colleagues in their report, published online by the Israeli government.
The researchers noted that it is difficult to account for differences between people in a real-world study.
People who choose to get a booster dose may be different from those who choose not to, and people behave differently after receiving an injection.
One important difference: recently vaccinated people are less likely to be tested for coronavirus infection, meaning fewer infections would be detected in that group.
Recently vaccinated people can also take extra care to prevent infection.